Drug-induced cardiotoxicity is one of the predominant reasons for drug attrition and withdrawals. This is of critical concern when potentially cardiotoxic drugs are administered to individuals with inherited arrhythmogenic cardiac diseases or with metabolic diseases such as obesity and diabetes, which are key risk factors for cardiovascular diseases. Pathophysiological alteration prevalent under such conditions can alter or exacerbate cardiotoxic responses. The growing incidence of obesity, diabetes and metabolic syndrome subject a significant percentage of the population to drug treatments, thereby augmenting their risk for drug-induced cardiovascular toxicity. Hence, screening for drug-induced cardiotoxicity early in the preclinical stages of drug development, by using appropriate human disease models, can be effective in ensuring safety in clinical trials and preventing late stage and post-marketing drug withdrawals owing to cardiotoxicity. The advent of human pluripotent stem cells (hPSC) and induced pluripotent stem cell (iPSC)-derived cardiomyocytes are revolutionizing safety/toxicity screening in human cells by providing relevant human-specific, renewable model systems to explore human drug toxicity. The ability to generate patient-specific iPSCs that can model cardiac diseases, now offers a valuable option that can further improve drug safety assessments and enable a more accurate prediction of toxicity that occurs in the representative population that are prescribed the drugs. Use of appropriate disease models will not only provide cost savings by decreasing potential drug attrition and withdrawals, seen with many drugs, but will also be a promising option to advance precision medicine
Introduction
The drug development pipeline is an arduous, labor-intensive and expensive process that entails stringent regulations by the FDA, in order to ensure the final marketed drug will be safe and efficacious for use in all patients that are prescribed the drugs [1] [2] [3] .
Although rigorous screening and testing of drugs occur as part of preclinical studies and clinical trials, safety and toxicity continue to be leading causes for the withdrawal of drugs from the markets [1, 4, 5] .
Amongst specific organ toxicities, cardiac toxicity is one of the predominant reasons for late-stage attrition of drugs [6] [7] [8] . A potential reason for late-stage drug attrition and post-marketing withdrawals may be attributed to drug-induce cardiotoxicity augmented by cardiovascular risk factors that are prevalent in many patients with metabolic disorders such as obesity (36% of the population [9] type II diabetes (9.3% of the population [10] , and metabolic syndrome (~35% of the population) [11] . Such patients are usually not part of clinical trials, unless the clinical trial is specifically for anti-diabetic or anti-obesity drugs.
Thus, drugs prescribed to a significant percentage of the population displaying cardiovascular risk factors put them at a higher risk for drug-induced cardiovascular toxicity.
Cardiovascular adverse events can result when drugs impact either the structural and functional aspects of the different components of the cardiovascular system including cardiac myocytes, fibroblasts, vascular smooth muscle cells and endothelial cells lining the vasculature, or affect the electrical conductivity of the heart or a combination of both, resulting in cardiac dysfunction [12] . Conditions that mediate drug-induced cardiotoxicity include 1) Cardiac arrhythmias: which results from the altered electrical conductivity of the heart causing tachycardia, brachycardia, ventricular fibrillation or asystole. [13] Torsade de pointes, is a dangerous form of ventricular arrhythmia, that is commonly triggered by cardiotoxic drugs [14] . It is characterized by tachycardia and associated with a prolonged QT interval in an electrocardiogram [12] .
2) Cardiac hypertrophy: This results from the increased size of the cardiomyocytes consequent to decreased or compromised cardiac function [15] . 3) Cardiomyopathy:
This is a condition that manifests due to structural and functional alterations in the heart resulting in decreased cardiac output [16] . 4) Congestive heart failure: Is a condition which occurs due to dysfunctional systoly, diastoly and myocardial contractility resulting in an inability to maintain cardiac output [17] Obesity is also associated with other risk factors for developing cardiac failure, such as hypertension, hyperlipidemia [26] and inflammation [24] . The presence of excess circulating free fatty acids (FFAs) in obesity can increase the delivery of FFAs to the heart resulting in cadiomyocyte lipotoxicity, augment reactive oxygen species (ROS) production and increase oxidative stress. [27] . Studies have shown that the accumulation of ROS in the myocardium consequent to hyperglycemia in the diabetic state can trigger myocardial apoptosis leading to diabetic cardiomyopathy [28] . Excess circulating FFAs in obesity activate toll receptors stimulating the downstream activation of the NFκB pathway resulting in augmented production of pro-inflammatory cytokines including TNFα and IL-6 [29] . TNFα can further increase the production of IL-6 and macrophage chemoattractant protein, (MCP-1), which plays a role in macrophage recruitment [24, 30] . These pro-inflammatory cytokines are prominent in stimulating the formation of atherosclerotic plaques [31] . The consequent state of chronic low-grade inflammation in obesity further plays a key role in the development of insulin resistance [24, 32] . Obesity and inflammation are associated with the development of endothelial dysfunction [33] . Diabetes is strongly associated with cardiovascular diseases and symptoms including atrial fibrillation, atrial flutter, coronary artery disease and left ventricular hypertrophy [34] and can contribute to the development of diabetic cardiomyopathy [35] . Thus, the pathophysiological changes accompanying obesity and diabetes exert their effects both at the cellular and systemic levels resulting in cardiac dysfunction [23, 36] Hence, the strategy of only examining the blockage of a single ion channel is increasingly being recognized as an imperfect measure ventricular repolarization [48, 49] .
Also, this much relied on in vitro assay for hERG, although highly sensitive, has only low specificity [49] .
Furthermore, nonclinical QT prolongation assays are not fully predictive of the QT prolongation in humans [48] .
Hence, although these guidelines have proven useful in decreasing drug-induced cardiotoxicity by enabling the early detection of potentially torsadogenic drugs, incidences of false positive results have led to the incorrect/inappropriate assignment of some drugs as torsadogenic [48] . In the case of some drugs, these approaches have also resulted in false negative results, leading to drug attrition [50] [51] [52] . In order to address these issue, partnered efforts by multidisciplinary scientists, representing international regulatory groups, industry and academia are underway for the development of more newer approaches to assess proarrhythmic risk under the Comprehensive in vitro Proarrhythmia Assay (CiPA) initiatives [49, 53] .
Limitations of current models and strategies
The move from animal and non-cardiac human cell lines to human human iPSC-derived cardiomyocytes are enabling the assessment of cardiotoxicity due to proarrhythmic cardiotoxic risk in more relevant human models. A significant limitation to the use of iPSC-derived cardiomyocytes is that they are recognized to exhibit a more neonatal phenotype as opposed to the preferred adult-like phenotype [54] . Many studies are addressing this issue to obtain a more adult-like phenotype in the iPSC-derived cardiomyocytes [54] . 
